title: Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis.
abstract: Patients with acute exacerbations of chronic bronchitis were treated with cefdinir 300 mg bd for 5 days or cefprozil 500 mg bd for 10 days in a prospective, randomized, double-blind, multicentre study. Of the 548 patients enrolled, 281 (51%) were evaluable. The clinical cure rates at the test-of-cure visit were 80% (114/142) and 72% (100/139) for the evaluable patients treated with cefdinir and cefprozil, respectively. Respiratory tract pathogens were isolated from 409 (75%) of 548 admission sputum specimens, with the predominant pathogens being Haemophilus parainfluenzae, Haemophilus influenzae, Staphylococcus aureus and Moraxella catarrhalis. The microbiological eradication rates at the test-of-cure visit were 81% (157 of 193 pathogens) and 84% (166 of 198 pathogens) for the evaluable patients treated with cefdinir and cefprozil, respectively. Adverse event rates while on treatment were equivalent between the two treatment groups. The incidence of diarrhoea during therapy was higher for patients treated with cefdinir (17%) than for patients treated with cefprozil (6%) (P < 0.01), but most cases were mild and did not lead to discontinuation of treatment. These results indicate that a 5 day regimen of cefdinir is as effective and safe in the treatment of patients with acute exacerbations of chronic bronchitis as a 10 day regimen of cefprozil.
authors.affiliation: Spartanburg Pharmaceutical Research, Spartanburg, SC. Edmonds Family Medicine Clinic, Edmonds, WA. Parke-Davis Pharmaceutical Research, Ann Arbor, MI, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Fogarty
authors.forename: R B
authors.initials: RB
authors.lastname: Bettis
authors.forename: T J
authors.initials: TJ
authors.lastname: Griffin
authors.forename: C H
authors.initials: CH
authors.lastname: Keyserling
authors.forename: M A
authors.initials: MA
authors.lastname: Nemeth
authors.forename: K J
authors.initials: KJ
authors.lastname: Tack
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D000077525:Cefdinir; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010612:Pharyngitis / Q000188:drug therapy / Q000382:microbiology; D011446:Prospective Studies; D014069:Tonsillitis / Q000188:drug therapy / Q000382:microbiology; D000097670:Cefprozil
chemical_list: D000890:Anti-Infective Agents; D000077525:Cefdinir; D002511:Cephalosporins; D000097670:Cefprozil